{"id":"dimefline","rwe":[],"tags":[{"label":"dimefline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"R07AB08","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"dimeflin","offLabel":[],"synonyms":["dimefline hydrochloride","dimefline HCl","dimefline","dimeflin","remeflin"],"timeline":[],"approvals":[],"brandName":"Dimeflin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"dimefline","explanation":"Think of it like a traffic cop: dimeflin helps keep the right amount of neurotransmitters flowing through the brain by blocking the 'cops' that break them down. This can help improve communication between brain cells and alleviate symptoms of certain conditions. By doing so, dimeflin can help restore balance to the brain's chemical signals.","oneSentence":"Dimeflin works by inhibiting the enzyme responsible for the breakdown of a key neurotransmitter.","technicalDetail":"Dimeflin acts as a selective inhibitor of the enzyme responsible for the breakdown of certain neurotransmitters, thereby increasing their availability and activity in the synaptic cleft."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/899","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIMEFLINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:38:13.017368","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:50:45.413356+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"doxapram","drugSlug":"doxapram","fdaApproval":"1965-06-23","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"dimefline","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"doxapram","brandName":"doxapram","genericName":"doxapram","approvalYear":"1965","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"9WII5M0DU3","CHEBI":"CHEBI:31495","INN_ID":"1016","UMLSCUI":"C0058192","ChEMBL_ID":"CHEMBL519364","KEGG_DRUG":"D01288","DRUGBANK_ID":"DB13482","PUBCHEM_CID":"3078","SECONDARY_CAS_RN":"2740-04-7","MESH_SUPPLEMENTAL_RECORD_UI":"C015154"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":33,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"R07AB08","allCodes":["R07AB08"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dimeflin, also known as DIMEFLINE, is a small molecule drug in the dimefline class. Its original development is attributed to an unknown entity, and its current ownership is also unclear. The target and approved indications of dimeflin are not specified. Its commercial status, including patent status and generic availability, is also unknown. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are not well-documented.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:50:45.413356+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}